This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Turner, M. S Articles by Stewart, D. W Search for Related Content PubMed PubMed Citation Articles by Turner, M. S Articles by Stewart, D. W Social Bookmarking                         What's this?

Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses

The Larkfield Centre, Lenzie, Glasgow, UK, Martin.Turner{at}glacomen.scot.nhs.uk

Duncan W Stewart

General Adult Psychiatry, Ravenscraig Hospital, Greenock, Inverclyde, Glasgow, UK

In schizophrenia, the objectives of long-term maintenance therapy are to achieve continuous relief from psychotic symptoms, to prevent relapse, to optimize patient functioning and improve quality of life. It is now generally accepted that atypical antipsychotic agents are more effective than conventional agents in achieving these goals over the short term. In order to define the role of atypical antipsychotics as maintenance treatment for schizophrenia, studies published between January 1994 and November 2005 that evaluated the long-term efficacy (1 year) of atypical antipsychotics for the treatment of schizophrenia were reviewed as identified from literature researches using MEDLINE and EMBASE. The primary research parameters were ‘atypical’, ‘antipsychotic’, ‘schizophrenia’, ‘relapse’, ‘long-term’, ‘maintenance’ and ‘efficacy’. Aspects of safety were also considered for these agents. Results from these long-term studies consistently demonstrated that atypical antipsychotics have substantial advantages over oral conventional antipsychotics as proven by fewer relapses, more effective symptom control and a lower incidence of movement disorders, although some atypical agents were associated with a higher incidence of weight gain. However, due to issues of compliance, the clinical advantage of oral atypical antipsychotics has often been limited. As such, the use of long-acting preparations of atypical antipsychotics, which provide consistent and sustained drug coverage, warrants further investigation for the successful long-term management of patients with schizophrenia.

Key Words: atypical antipsychotic • compliance • long-term efficacy • long-acting injectable • maintenance therapy • risperidone • psychoses • relapse • safety • schizophrenia

Journal of Psychopharmacology, Vol. 20, No. 6 suppl, 20-37 (2006)
DOI: 10.1177/1359786806071243


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Dolder, M. Nelson, and Z. Deyo Paliperidone for schizophrenia Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 403 - 413. [Abstract] [Full Text] [PDF]

				H. A. Nasrallah and S. M. Dursun Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy J Psychopharmacol, November 1, 2006; 20(6_suppl): 3 - 5. [PDF]